Consumer group calls on AstraZeneca to pull Crestor ads

Share this article:
Consumer advocacy group, Public Citizen, is calling on AstraZeneca to pull its latest newspaper ads for Crestor, charging that the ads make false claims about FDA's  concerns over the drug's safety.
"I urge that the FDA immediately stop AstraZeneca from running this or any other misleading advertising about Crestor," wrote Public Citizen's health research group director, Sidney Wolfe, in a letter sent to the FDA's acting commissioner, Lester Crawford, last week.
"The FDA has confidence in the safety and efficacy of Crestor," states  the full-page, color ads that began appearing in The New York Times, USA Today and The Wall Street Journal earlier this month, soon after a veteran FDA scientist named the drug as one of five currently marketed drugs that need more scrutiny.
However, the ad claims that the "concerns that have been raised have no medical or scientific basis."
Calling Public Citizen's concerns "absurd," an AstraZeneca spokesman told Reuters, "We've been assured at the highest level of the FDA that there are no new concerns with Crestor."
Share this article:

Email Newsletters

More in News

Doctors want to know how CMS plans to display Sunshine payment data

Doctors want to know how CMS plans to ...

Physician and industry trade groups are asking CMS to explain how context will be provided to the general public around the dollar sums drugmakers ascribe to doctors for things like ...

Pfizer Q2 sales slip, but still beat expectations

Pfizer Q2 sales slip, but still beat expectations

Patent losses and lost co-promotion agreements put a dent in sales.

Lack of marketing partner delays Afrezza launch

Lack of marketing partner delays Afrezza launch

Afrezza was heralded as one of the most innovative diabetes products of the last decade. So, why hasn't MannKind set a firm launch date for the product?